In Depth 1 Aug 2024 CureVac: From a failed drug to a €1.45 billion deal In 2021, CureVac’s COVID-19 candidate came short. Discover how the company leveraged its deal with GSK to restructure and turn things around. August 1, 2024 - 8 minutesmins - By Jules Adam Share WhatsApp Twitter Linkedin Email
In Depth 30 Jul 2024 Why is the immunology and inflammation market suddenly attracting a wave of investment? Discover why the immunology and inflammation market has recently been attracting a major wave of investment. July 30, 2024 - 13 minutesmins - By Willow Shah-Neville Share WhatsApp Twitter Linkedin Email
In Depth 25 Jul 2024 The future of inflammatory bowel disease treatment: what is on the horizon? Ongoing clinical trials aim to address inflammatory bowel disease, which is caused by an overactive immune system that causes symptoms affecting the gut. July 25, 2024 - 8 minutesmins - By Roohi Mariam Peter Share WhatsApp Twitter Linkedin Email
In Depth 24 Jul 2024 Danuglipron: Is Pfizer’s oral weight loss pill a contender in the obesity market? Find out more about Pfizer’s GLP-1 candidate danuglipron, as the company aims to compete in the obesity market. July 24, 2024 - 10 minutesmins - By Willow Shah-Neville Share WhatsApp Twitter Linkedin Email
In Depth 18 Jul 2024 Lenacapavir: Can Gilead’s drug end the HIV pandemic? Discover more about Gilead’s lenacapavir, which recently demonstrated 100% efficacy for HIV prevention in a phase 3 trial. July 18, 2024 - 7 minutesmins - By Willow Shah-Neville Share WhatsApp Twitter Linkedin Email
In Depth 15 Jul 2024 Fighting EEHV in elephants: How mRNA vaccines can offer hope against viruses affecting animals Discover how a new mRNA vaccine could help to tackle EEHV in elephants, which is a number one killer of Asian elephant calves. July 15, 2024 - 8 minutesmins - By Willow Shah-Neville Share WhatsApp Twitter Linkedin Email
In Depth 10 Jul 2024 Biotech’s battle against skeletal dysplasia: Ray of hope for children with rare genetic disorder As treatments for skeletal dysplasia are intended to alleviate painful symptoms, two drugs are battling out in the clinic to prove their effectiveness. July 10, 2024 - 7 minutesmins - By Roohi Mariam Peter Share WhatsApp Twitter Linkedin Email
In Depth 8 Jul 2024 Bridge RNA: A new gene editing technique that could overcome the limitations of CRISPR Find out how the recent discovery of a molecular oddity found in bacteria has led to a new gene editing technique. July 8, 2024 - 5 minutesmins - By Willow Shah-Neville Share WhatsApp Twitter Linkedin Email
In Depth 4 Jul 2024 The biggest private biotech investments in June 2024 The companies Formation Bio, Isotopen Technologien München, and Marea Therapeutics bagged the biggest private biotech investments in June 2024. July 4, 2024 - 2 minutesmins - By Willow Shah-Neville Share WhatsApp Twitter Linkedin Email
In Depth 1 Jul 2024 Special Olympics: How is biotechnology revolutionizing sports performance worldwide? Find out about biotechnology’s impact on sports performance and recovery, from genetic profiling, stem cells, and wearable technologies. July 1, 2024 - 5 minutesmins - By Willow Shah-Neville Share WhatsApp Twitter Linkedin Email
In Depth 28 Jun 2024 Going nuclear: radiopharmaceuticals funding sees surge in 2024 Emerging as a new class of drugs, radiopharmaceuticals are all the rage in cancer treatment research as biotechs nab major funding deals. June 28, 2024 - 6 minutesmins - By Roohi Mariam Peter Share WhatsApp Twitter Linkedin Email
In Depth 27 Jun 2024 CRISPR-Cas13: how does the technology compare to its famous Cas9 cousin? Discover more about CRISPR-Cas13, including how it differs from CRISPR-Cas9 and what the technology can be used for. June 27, 2024 - 7 minutesmins - By Willow Shah-Neville Share WhatsApp Twitter Linkedin Email